Illumina, Inc.
Illumina Reports Q4 and FY 2025 Financial Results
Summary
Illumina, Inc. reported its financial results for Q4 and FY 2025, showing a 5% increase in Q4 revenue and flat revenue for FY 2025 compared to the previous year. The company reported a GAAP operating margin of 17.4% and a non-GAAP operating margin of 23.7% for Q4. For FY 2025, the GAAP operating margin was 18.6%, and the non-GAAP operating margin was 23.1%. The company also provided guidance for FY 2026, expecting total revenue between $4.5 billion and $4.6 billion, representing growth of 4% - 6%.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement